## John Gierula

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2197382/publications.pdf

Version: 2024-02-01

623734 552781 48 734 14 26 citations g-index h-index papers 48 48 48 1306 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Diabetes mellitus and the causes of hospitalisation in people with heart failure. Diabetes and Vascular Disease Research, 2022, 19, 147916412110739.	2.0	1
2	Association of heart failure and its comorbidities with loss of life expectancy. Heart, 2021, 107, 1417-1421.	2.9	21
3	Cardiac contractility modulation for the treatment of heart failure with reduced ejection fraction. Heart Failure Reviews, 2021, 26, 217-226.	3.9	10
4	Advanced care planning during the COVID-19 pandemic: ceiling of care decisions and their implications for observational data. BMC Palliative Care, 2021, 20, 10.	1.8	18
5	Impact of the COVID-19 pandemic on the management of chronic heart failure. Reviews in Cardiovascular Medicine, 2021, 22, 271.	1.4	2
6	Diabetes, gender and deterioration in estimated glomerular filtration rate in patients with chronic heart failure: Ten-year prospective cohort study. Diabetes and Vascular Disease Research, 2021, 18, 147916412098443.	2.0	1
7	Quantifying the relationship and contribution of mitochondrial respiration to systemic exercise limitation in heart failure. ESC Heart Failure, 2021, 8, 898-907.	3.1	2
8	Detrimental Immediate- and Medium-Term Clinical Effects of Right Ventricular Pacing in Patients With Myocardial Fibrosis. Circulation: Cardiovascular Imaging, 2021, 14, e012256.	2.6	3
9	To the Editorâ€"New phones, old problem? Interference with cardiovascular implantable electronic devices by phones containing magnets. Heart Rhythm, 2021, 18, 1041.	0.7	13
10	We Do Not Talk to Patients About Their Prognosis, But Is Any of This Surprising?. Journal of Cardiac Failure, 2021, 27, 1479-1480.	1.7	0
11	Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure. Journal of Cardiovascular Medicine, 2021, 22, 848-856.	1.5	6
12	Advances in cardiac resynchronization and implantable cardioverter/defibrillator therapy: Medtronic Cobalt and Crome. Future Cardiology, 2021, 17, 609-618.	1.2	0
13	OUP accepted manuscript. Europace, 2021, , .	1.7	O
14	Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial. PLoS ONE, 2021, 16, e0259450.	2.5	0
15	Divergent skeletal muscle mitochondrial phenotype between male and female patients with chronic heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 79-88.	7.3	15
16	Chronic heart failure with diabetes mellitus is characterized by a severe skeletal muscle pathology. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 394-404.	7.3	20
17	A CARDIOMETABOLIC RESERVE IN HEART FAILURE, REVEALED BY VERIFICATION PHASE EXERCISE TESTING, DOES NOT CONFER PROGNOSTIC BENEFIT. Chest, 2020, 158, A2056-A2057.	0.8	0
18	Prioritizing symptom management in the treatment of chronic heart failure. ESC Heart Failure, 2020, 7, 2193-2207.	3.1	32

#	Article	IF	Citations
19	Feasibility and validation of trans-valvular flow derived by four-dimensional flow cardiovascular magnetic resonance imaging in pacemaker recipients. Magnetic Resonance Imaging, 2020, 74, 46-55.	1.8	5
20	Unique Transcriptome Signature Distinguishes Patients With Heart Failure With Myopathy. Journal of the American Heart Association, 2020, 9, e017091.	3.7	11
21	Longâ€term performance of left ventricular leads in cardiac resynchronisation therapy. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1501-1507.	1.2	1
22	Infection-Related Hospitalization in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006746.	3.9	39
23	Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure. Circulation, 2020, 141, 1693-1703.	1.6	12
24	Effect of diseaseâ€modifying agents and their association with mortality in multiâ€morbid patients with heart failure with reduced ejection fraction. ESC Heart Failure, 2020, 7, 3859-3870.	3.1	7
25	Response by Gierula et al to Letter Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study― Circulation, 2020, 142, e319-e320.	1.6	0
26	Predicting oneâ€year mortality in heart failure using the â€~Surprise Question': a prospective pilot study. European Journal of Heart Failure, 2019, 21, 227-234.	7.1	40
27	Vitamin D deficiency is an independent predictor of mortality in patients with chronic heart failure. European Journal of Nutrition, 2019, 58, 2535-2543.	3.9	23
28	Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial. BMJ Open, 2019, 9, e028613.	1.9	2
29	Prognostic Significance of Incidental Nonsustained Ventricular Tachycardia Detected on Pacemaker Interrogation. American Journal of Cardiology, 2019, 123, 409-413.	1.6	8
30	Prospective evaluation and long-term follow-up of patients referred to secondary care based upon natriuretic peptide levels in primary care. European Heart Journal Quality of Care & Dinical Outcomes, 2019, 5, 218-224.	4.0	3
31	Cardiac magnetic resonance in patients with cardiac resynchronization therapy: is it time to scan with resynchronization on?. Europace, 2019, 21, 554-562.	1.7	1
32	Devices in heart failure; diagnosis, detection and disease modification. British Medical Bulletin, 2018, 125, 91-102.	6.9	3
33	Rate-Response Programming Tailored toÂthe Force-Frequency Relationship Improves Exercise Tolerance in ChronicÂHeart Failure. JACC: Heart Failure, 2018, 6, 105-113.	4.1	14
34	Prevalence and Predictors of Sepsis Death in Patients With Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction. Journal of the American Heart Association, 2018, 7, e009684.	3.7	52
35	Ischemic Heart Disease Modifies the Association of Atrial Fibrillation With Mortality in Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2018, 7, e009770.	3.7	9
36	Mortality Reduction Associated With $\hat{l}^2$ -Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes. Diabetes Care, 2018, 41, 136-142.	8.6	32

#	Article	IF	CITATIONS
37	Cardiac resynchronization therapy outcomes in patients with chronic heart failure. Journal of Cardiovascular Medicine, 2017, 18, 962-967.	1.5	10
38	Performance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification. Heart, 2016, 102, 735-740.	2.9	3
39	Effects of Vitamin D on Cardiac Function inÂPatients With Chronic HF. Journal of the American College of Cardiology, 2016, 67, 2593-2603.	2.8	179
40	Chronotropic Incompetence DoesÂNotÂLimit Exercise Capacity inÂChronicÂHeartÂFailure. Journal of the American College of Cardiology, 2016, 67, 1885-1896.	2.8	32
41	Reply. Journal of the American College of Cardiology, 2016, 68, 1253.	2.8	0
42	Ambulatory heart rate range predicts mode-specific mortality and hospitalisation in chronic heart failure. Heart, 2016, 102, 223-229.	2.9	20
43	Patients with long-term permanent pacemakers have a high prevalence of left ventricular dysfunction. Journal of Cardiovascular Medicine, 2015, 16, 743-750.	1.5	10
44	Calcium, phosphate and calcium phosphate product are markers of outcome in patients with chronic heart failure. Journal of Nephrology, 2015, 28, 209-215.	2.0	21
45	Pacing-associated left ventricular dysfunction? Think reprogramming first!. Heart, 2014, 100, 765-769.	2.9	12
46	Septal Pacing: Still No Clarity?. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 263-264.	1.2	6
47	Response to (resynchronization) therapy in chronic heart failure: time for a different approach. European Journal of Heart Failure, 2014, 16, 117-118.	7.1	4
48	Cardiac resynchronization therapy in pacemaker-dependent patients with left ventricular dysfunction. Europace, 2013, 15, 1609-1614.	1.7	31